Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials

BACKGROUND: ATX-101 (deoxycholic acid injection) is the only injectable drug approved for submental fat (SMF) reduction. In the phase 3 REFINE trials, adults with moderate or severe SMF who were dissatisfied with the appearance of their face/chin were eligible to receive up to 6 treatment sessions w...

Descripción completa

Detalles Bibliográficos
Autores principales: Dayan, Steven H, Schlessinger, Joel, Beer, Kenneth, Donofrio, Lisa M, Jones, Derek H, Humphrey, Shannon, Carruthers, Jean, Lizzul, Paul F, Gross, Todd M, Beddingfield, Frederick C, Somogyi, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Cosmetic Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094350/
https://www.ncbi.nlm.nih.gov/pubmed/29401213
http://dx.doi.org/10.1093/asj/sjy008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094350/
https://www.ncbi.nlm.nih.gov/pubmed/29401213
http://dx.doi.org/10.1093/asj/sjy008

Ejemplares similares